- 1815-2015 (online)
This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language - English or French - with a summary in the other.
Value in Pharmaceutical Pricing
Click to Access:
- Valérie Paris1, Annalisa Belloni1
- Author Affiliations
- 1: OECD, France
- 11 July 2013
- Bibliographic information
This study analyses how 14 OECD Countries refer to "value" when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes which dimensions are taken into account in the assessment of "innovativeness" and the consequences of this assessment on prices; it confirms that treatments for severe and/or rare diseases are often more valued than others and shows how countries use product-specific agreements in an attempt to better align value and price.
- JEL Classification:
- I18: Health, Education, and Welfare / Health / Government Policy; Regulation; Public Health